AngioChem is a Montreal-based biotechnology company dedicated to creating and developing novels therapies which traverse the Blood-Brain Barrier to treat diseases of the brain. AngioChem leverages a breakthrough technology capable of transporting any size of molecule to the brain. To validate the potential of this broad-based platform technology, the company will soon be entering clinical development for its lead program targeting brain cancer. AngioChem has also extended the use of its technology to transport monoclonal antibodies to the brain. AngioChem will enter into collaborative research and development programs with biotechnology and pharmaceutical companies whose compounds' therapeutic indices could be greatly enhanced by the Angiochem platform.
141 President Kennedy
Montreal, Quebec H2X 3Y7